Anxiety Therapy Market to Reach $4.26B by 2033, Boosting BrainsWay Opportunity
Global market for generalized anxiety disorder therapies is projected to rise from $1.8 billion in 2023 to $4.26 billion by 2033, achieving ~9% annual growth. Broader anxiety treatment revenues could surpass $12 billion to $17 billion over the next decade, underlining potential upside for BrainsWay’s neuromodulation and digital therapy segments.
1. GAD Therapy Market Forecast
The market for Generalized Anxiety Disorder therapies was valued at approximately $1.8 billion in 2023 and is expected to expand to $4.26 billion by 2033, representing roughly 9% annual growth. Analysts also project the wider anxiety treatment sector could reach between $12 billion and $17 billion over the next decade as patient demand rises.
2. Treatment Modalities Driving Growth
Traditional anti-anxiety medications and antidepressants continue to hold significant share, while cognitive-behavioral therapy, mindfulness techniques and telehealth-delivered mental health services are rapidly expanding. Digital mental health tools, including app-based cognitive therapies and remote clinician consultations, are lowering access barriers and attracting investment.
3. BrainsWay’s Position in the Market
BrainsWay, a leading provider of neuromodulation solutions, stands to benefit from this market expansion through its noninvasive deep transcranial magnetic stimulation platforms. The company’s focus on combining technology-driven treatment with digital support services aligns with industry trends toward personalized, clinic-based and remote anxiety therapies.